S
Suzanne Kafaja
Researcher at University of California, Los Angeles
Publications - 45
Citations - 3369
Suzanne Kafaja is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Placebo & Population. The author has an hindex of 17, co-authored 38 publications receiving 2415 citations.
Papers
More filters
Journal ArticleDOI
American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis
Bevra H. Hahn,Maureen McMahon,Alan H. Wilkinson,W. Dean Wallace,David I. Daikh,John FitzGerald,George Karpouzas,Joan T. Merrill,Daniel J. Wallace,Jinoos Yazdany,Rosalind Ramsey-Goldman,Karandeep Singh,Mazdak A. Khalighi,Soo I. Choi,Maneesh Gogia,Suzanne Kafaja,Mohammad Kamgar,Christine Lau,William J. Martin,Sefali Parikh,Justin Peng,Anjay Rastogi,Weiling Chen,Jennifer M. Grossman +23 more
TL;DR: The management strategies discussed here apply to lupus nephritis in adults, particularly to those receiving care in the United States of America, and include interventions that were available in theUnited States as of April 2011.
Journal ArticleDOI
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial
Donald P. Tashkin,Michael D. Roth,Philip J. Clements,Daniel E. Furst,Dinesh Khanna,Eric C. Kleerup,Jonathan G. Goldin,Edgar Arriola,Elizabeth R. Volkmann,Suzanne Kafaja,Richard M. Silver,Virginia D. Steen,Charlie Strange,Robert A. Wise,Fredrick M. Wigley,Maureen D. Mayes,David J. Riley,Sabiha Hussain,Shervin Assassi,Vivien Hsu,Bela Patel,Kristine Phillips,Fernando J. Martinez,Jeffrey A. Golden,M. Kari Connolly,John Varga,Jane Dematte,Monique Hinchcliff,Aryeh Fischer,Jeffrey J. Swigris,Richard T. Meehan,Arthur C. Theodore,Robert W. Simms,Suncica Volkov,Dean E. Schraufnagel,Mary Beth Scholand,Tracy M. Frech,Jerry A. Molitor,Kristin B. Highland,Charles A. Read,Marvin J. Fritzler,Grace Kim,Chi-Hong Tseng,Robert Elashoff +43 more
TL;DR: In this article, the authors used a modified intention-to-treat analysis using an inferential joint model combining a mixed-effects model for longitudinal outcomes and a survival model to handle non-ignorable missing data.
Journal ArticleDOI
Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.
Keith M. Sullivan,Ellen Goldmuntz,Lynette Keyes-Elstein,Peter A. McSweeney,Ashley Pinckney,Beverly Welch,Maureen D. Mayes,Richard A. Nash,Leslie J. Crofford,Barry Eggleston,Sharon Castina,Linda M. Griffith,Julia S. Goldstein,Dennis Wallace,Oana Craciunescu,Dinesh Khanna,Rodney J. Folz,Jonathan G. Goldin,E. W. Clair,James R. Seibold,Kristine Phillips,Shin Mineishi,Robert W. Simms,Karen K. Ballen,Mark H. Wener,George E. Georges,Shelly Heimfeld,Chitra Hosing,Stephen J. Forman,Suzanne Kafaja,Richard M. Silver,L. Griffing,Jan Storek,Sharon LeClercq,R. Brasington,Mary Ellen Csuka,Christopher Bredeson,Carolyn A. Keever-Taylor,R.T. Domsic,M. B. Kahaleh,Thomas A. Medsger,Daniel E. Furst,Daniel E. Furst +42 more
TL;DR: Myeloablative autologous hematopoietic stem‐cell transplantation achieved long‐term benefits in patients with scleroderma, including improved event‐free and overall survival, at a cost of increased expected toxicity.
Journal ArticleDOI
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Dinesh Khanna,Celia J. F. Lin,Daniel E. Furst,Jonathan G. Goldin,Grace Kim,Masataka Kuwana,Yannick Allanore,Marco Matucci-Cerinic,Oliver Distler,Yoshihito Shima,Jacob M van Laar,Helen Spotswood,Bridget Wagner,Jeffrey Siegel,Angelika Jahreis,Christopher P. Denton,Eleonora Lucero,Bernardo A. Pons-Estel,Mariano Rivero,Guillermo Tate,Vanessa Smith,Ellen De Langhe,Rasho Rashkov,Anastas Batalov,Ivan Goranov,Rumen Stoilov,James V. Dunne,Sindhu R. Johnson,Janet E. Pope,Dušanka Martinović Kaliterna,Mette Mogensen,Anne Braae Olesen,Joerg Henes,Ulf Müller-Ladner,Gabriela Riemekasten,Alla Skapenko,Panayiotis G. Vlachoyiannopoulos,Emese Kiss,Tünde Minier,Lorenzo Beretta,Elisa Gremese,Gabriele Valentini,Yoshihide Asano,Tatsuya Atsumi,Hironobu Ihn,Tomonori Ishii,Osamu Ishikawa,Hiroki Takahashi,Kazuhiko Takehara,Yoshiya Tanaka,Yoshioki Yamasaki,Loreta Bukauskiene,Irena Butrimiene,Gabriel Medrano Ramirez,Cesar Ramos-Remus,Tatiana Sofia Rodriguez Reyna,Jeska K de Vries-Bouwstra,Bogdan Batko,Sławomir Jeka,Eugeniusz J. Kucharz,Maria Majdan,Marzena Olesińska,Zaneta Smolenska,Jose Alves,Maria José Santos,C. Mihai,Simona Rednic,Ivan Castellvi Barranco,Francisco Javier Lopez Longo,Carmen Simeon Aznar,Patricia Carreira,Ulrich A. Walker,Emma Derrett-Smith,Bridget Griffiths,Neil McKay,Jacob Aelion,Michael S. Borofsky,Roy Fleischmann,Joseph Z. Forstot,Suzanne Kafaja,M. Faisal Khan,Michael D. Kohen,Richard J. Martin,Fabian Mendoza-Ballesteros,Alireza Nami,Shirley Pang,Grissel Rios,Robert W. Simms,Keith M. Sullivan,Virginia D. Steen +89 more
TL;DR: Findings for the secondary endpoint of FVC% predicted indicate that tocilizumab might preserve lung function in people with early SSc-ILD and elevated acute-phase reactants.
Journal ArticleDOI
Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator‐Initiated, Multicenter, Double‐Blind, Randomized, Placebo‐Controlled Trial
Dinesh Khanna,Cathie Spino,Sindhu R. Johnson,Lorinda Chung,Michael L. Whitfield,Christopher P. Denton,Veronica J. Berrocal,Jennifer M. Franks,Bhavan Mehta,Jerry A. Molitor,Virginia D. Steen,Robert Lafyatis,Robert W. Simms,Anna Gill,Suzanne Kafaja,Tracy M. Frech,Vivien Hsu,Robyn T. Domsic,Janet E. Pope,Jessica K. Gordon,Maureen D. Mayes,Elena Schiopu,Amber Young,Nora Sandorfi,Jane Park,Faye N. Hant,Elana J. Bernstein,Soumya Chatterjee,Flavia V. Castelino,Ali Ajam,Yue Wang,Tammara A. Wood,Yannick Allanore,Marco Matucci-Cerinic,Oliver Distler,Ora Singer,Erica Bush,David A. Fox,Daniel E. Furst +38 more
TL;DR: T cells play a key role in the pathogenesis of early systemic sclerosis and the safety and efficacy of abatacept in patients with diffuse cutaneous systemic sclerosis was assessed.